References
- Jiang M, Stanke J, Lahti JM. The connections between neural crest development and Neuroblastoma. Curr Top Dev Biol. 2011;94:77–127.
- Brodeur GM. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203–216.
- St. Jude's Children Research Hospital Website. Neuroblastoma. https://www.stjude.org/disease/neuroblastoma.html (Accessed 06 14, 2017).
- Nuchtern JG, London WB, Barnewolt CE, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg. 2012;256:573–580.
- Park JR, Eggert A, Caron H. Neuroblastoma: Biology, prognosis, and treatment. Pediatr Clin North Am. 2008;55:97–120.
- PDQ® Pediatric Treatment Editorial Board. PDQ neuroblastoma treatment. Bethesda, MD: National Cancer Institute. Updated 04/14/2017. Available at: https://www.cancer.gov/types/neuroblastoma/patient/neuroblastoma-treatment-pdq. Accessed 06/15/2017.
- Matthay KK, Maris JM, Schleiermacher G, et al. Neuroblastoma. Nat Rev Dis Primer. 2016;2:16078.
- Pinto NR, Applebaum MA, Volchenboum SL, et al. Advances in risk classification and treatment strategies for Neuroblastoma. J Clin Oncol. 2015;33:3008–3017.
- Park JR, Bagatell R, London WB, et al. Children's oncology group's 2013 blueprint for research: Neuroblastoma. Pediatr Blood Cancer. 2013;60:985–993.
- Surveillance Research Program. Number of persons by race and hispanic ethnicity for SEER Participants (2010 Census Data). Bethesda, MD. http://seer.cancer.gov/registries/data.html. Accessed 01/06/2017.
- Banegas MP, Harlan LC, Mann B, Yabroff KR. Renal cell cancer: A shift in approaches for treatment of advanced disease in the United States. J Natl Compr Cancer Netw. 2014;12:1271–1279.
- Harlan LC, Eisenstein J, Russell MC, Stevens JL, Cardona K. Gastrointestinal stromal tumors: Treatment patterns of a population-based sample. J Surg Oncol. 2015;111:702–707.
- Patterns of Care/Quality of Care Studies. Bethesda, MD: National Cancer Institute. Updated 02/24/2017. Available at: https://healthcaredelivery.cancer.gov/poc/ Accessed 06/12/2017.
- Di Cataldo A, Agodi A, Balaguer J, et al. Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials? Clin Transl Oncol. 2017;19(1):76–83.
- Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17:369–386.
- Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010;363:1313–1323.
- Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the childhood cancer survivor study: A multi-institutional collaborative project. Med Pediatr Oncol. 2002;38:229–239.
- FDA Press Announcements – FDA approves first therapy for high-risk neuroblastoma. Silver Spring, MD: Food and Drug Administration. Updated 03/10/2015. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm437460.htm. Accessed 04/20/2017.
- Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–1334.
- Mackall CL, Merchant MS, Fry TJ. Immune-based therapies for childhood cancer. Nat Rev Clin Oncol. 2014;11:693–703.
- Navid F, Armstrong M, Barfield RC. Immune therapies for Neuroblastoma. Cancer Biol Ther. 2009;8:874–882.
- Ganeshan VR, Schor NF. Pharmacologic management of high-risk neuroblastoma in children. Paediatr Drugs. 2011;13:245–255.
- Strother DR, London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol. 2012;30:1842–1848.
- Laverdière C, Liu Q, Yasui Y, et al. Long-term outcomes in survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009;101:1131–1140.